Published in Cancer Weekly, September 23rd, 2003
Prior to the decision, NICE had recommended that newly diagnosed patients in the chronic phase of CML could only receive Glivec following failure or intolerance to Interferon-alpha, a less effective therapy with unpleasant side effects, which can seriously affect quality of life.
Shazia Breay, medical manager, Novartis...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.